Do you want to read an article? Please log in or register.
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up
Amyloidosis
Related content
SPECIAL REPORT
Multiple Myeloma (MM)
Traitement du myélome multiple récidivant/réfractaire
EHA® 25 Virtual
Multiple Myeloma (MM)
Amyloid light-chain (AL) amyloidosis
SPECIAL REPORT
Multiple Myeloma (MM)
Therapie des rezidivierten/refraktären Multiplen Myeloms
Multiple Myeloma (MM)
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Haematologica.
Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ
doi: 10.3324/haematol.
RECOMMENDED
Multiple Myeloma (MM)
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
★ 1
Recommended by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1200/JCO.19.02515.
RECOMMENDED
Lymphoma
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
Hematol Oncol.
Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y
doi: 10.1002/hon.2560.
Lymphoma
Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
Oncologist.
Gandolfi L, Pellegrini C, Casadei B, Stefoni V, Broccoli A, Tonialini L, Morigi A, Argnani L, Zinzani PL
doi: 10.1634/
RECOMMENDED
Multiple Myeloma (MM)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, OPTIMISMM trial investigators.
doi: 10.1016/S1470-2045(19)30152-4.
COMMENTED
Multiple Myeloma (MM)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
Lancet.
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ
doi: 10.1016/S0140-6736(20)30734-0.